Advertisement


Basem Azab, MD, on Esophageal Cancer: Study Survival Results

2018 Gastrointestinal Cancers Symposium

Advertisement

Basem Azab, MD, of the Sylvester Comprehensive Cancer Center, University of Miami, discusses the impact on overall survival when more than 2 months elapse between finishing neoadjuvant therapy and undergoing esophagectomy (Abstract 2).



Related Videos

Gastrointestinal Cancer
Immunotherapy

Florian Lordick, MD, on Gastric Cancer: Final Results From the AIO Trial

Florian Lordick, MD, of the University Medicine Leipzig, discusses study findings on intraperitoneal immunotherapy with the antibody catumaxomab for patients with peritoneal carcin...

Gastroesophageal Cancer

Abraham J. Wu, MD, on Esophageal Cancer: Impact of Lung and Heart Dose on Survival After Radiotherapy

Abraham J. Wu, MD, of Memorial Sloan Kettering Cancer Center, discusses his findings that suggest efforts to reduce lung dose, such as shrinking the treatment volumes or usin...

Pancreatic Cancer

Ramesh K. Ramanathan, MD, on Metastatic Pancreatic Cancer: Results From a SWOG Study

Ramesh K. Ramanathan, MD, of the Mayo Clinic, discusses early-phase study findings on mFOLFIRINOX (mFFOX) plus pegylated recombinant human hyaluronidase vs mFFOX alone in patients ...

Gastroesophageal Cancer

David H. Ilson, MD, PhD, on Improving Esophageal Cancer Outcomes: Future Directions

David H. Ilson, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the merits of preoperative chemotherapy vs chemoradiotherapy, the role of targeted agents, recent resu...

Gastroesophageal Cancer
Gastrointestinal Cancer

Maria Svensson, MD, PhD Candidate, on Esophageal and Gastric Cancers: Significance of PD-1 and PD-L1 Expression

Maria Svensson, MD, PhD Candidate, of Lund University, discusses high expression of PD-1 and PD-L1 in chemotherapy-naive esophageal and gastric adenocarcinomas, the implicati...

Advertisement

Advertisement



;
Advertisement